Ocumension Therapeutics
HKEX:1477
Ocumension Therapeutics
Operating Income
Ocumension Therapeutics
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Ocumension Therapeutics
HKEX:1477
|
Operating Income
-¥405.5m
|
CAGR 3-Years
43%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Operating Income
¥2.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Operating Income
¥3.5B
|
CAGR 3-Years
21%
|
CAGR 5-Years
22%
|
CAGR 10-Years
22%
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Operating Income
¥4.8B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
1%
|
CAGR 10-Years
12%
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Operating Income
¥3.9B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Operating Income
-¥749.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Ocumension Therapeutics's Operating Income?
Operating Income
-405.5m
CNY
Based on the financial report for Dec 31, 2023, Ocumension Therapeutics's Operating Income amounts to -405.5m CNY.
What is Ocumension Therapeutics's Operating Income growth rate?
Operating Income CAGR 5Y
-14%
Over the last year, the Operating Income growth was 10%. The average annual Operating Income growth rates for Ocumension Therapeutics have been 43% over the past three years , -14% over the past five years .